Alex Sapir - 19 May 2023 Form 4 Insider Report for PhaseBio Pharmaceuticals Inc

Role
Director
Signature
/s/ Jonathan P. Mow, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
19 May 2023
Net transactions value
$0
Form type
4
Filing time
19 May 2023, 16:17:17 UTC
Previous filing
20 May 2022
Next filing
03 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHASQ Common Stock Options Exercise +3,750 3,750 19 May 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHASQ Restricted Stock Units Options Exercise $0 -3,750 -100% $0.000000* 0 19 May 2023 Common Stock 3,750 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.
F2 The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date.